The text provides detailed information on the financial statements of Merck & Co., Inc., for the period ending in September 2022. It covers aspects such as sales, costs, expenses, income from continuing operations, earnings per share, assets, liabilities, equity structure, and disclosures related to accounting standards. The company has shown growth in net income and implemented new accounting standards while ensuring overall financial stability. Additionally, it describes the company's usage of derivative contracts to hedge foreign currency exposure and forecasted transactions, detailing topics such as unrealized gains on derivatives, fair value measurements, contingent consideration from business combinations, credit risk concentrations, inventory composition, and accounting treatment of collateral received from counterparties.
Merck recently appointed Robert M. Davis as chairman of the board and engaged in significant collaborations with various companies. The completion of the product spin-off into Organon & Co. was also a notable development. The financial impacts of global events like the war in Ukraine and the COVID-19 pandemic were discussed. While certain pharmaceutical products like Keytruda, Lynparza, Lenvima, and Reblozyl showed positive revenue growth, sales of Januvia and Janumet declined due to various factors. Restructuring efforts aimed to optimize manufacturing and reduce costs are ongoing, and research and development expenses increased. Despite challenges, Merck achieved profit growth in both its Pharmaceutical and Animal Health segments.
There have been no significant changes in market risk exposures as reported in the Company's 2021 Form 10-K. The Turkish economy was identified as hyperinflationary, leading to the remeasurement of the Company's monetary assets and liabilities in the second quarter of 2022 under U.S. GAAP. This adjustment minimally impacted Merck's consolidated financial statements.
Management of the Company has evaluated and deemed effective the disclosure controls and procedures over financial reporting as of September 30, 2022, with no material changes in internal controls noted for the third quarter of 2022. The report contains forward-looking statements based on current expectations, cautioning readers about the uncertainties and risks involved which may lead to actual results differing from these statements. The company does not commit to updating forward-looking statements and advises readers to consider factors mentioned in their filings with the Securities and Exchange Commission to fully understand risks and uncertainties potentially impacting future results. Investors should bear in mind that not all risk factors are predictable or identifiable, and no list can comprehensively cover all potential risks or uncertainties.
The text refers to legal proceedings information being incorporated by reference to Note 9 in the Part I, Item 1, Financial Statements of the Condensed Consolidated Financial Statements.
The ongoing war between Russia and Ukraine, along with global disruptions and sanctions, could negatively impact the Company's business operations and financial condition. The Company is actively monitoring and mitigating interruptions to business continuity, including effects on its supply chain and clinical trials. Despite currently supplying essential medicines in Russia, the Company has no further investment plans in the country and has suspended screening and enrollment in clinical trials. Financially, the impact of the war on the Company was not significant in 2022, but future implications are uncertain and may depend on various external factors. These uncertainties could heighten existing risks that were disclosed in the Company's Annual Report.
The text provided details issuer purchases of equity securities for the three months ended September 30, 2022. It lists the purchases in terms of periods, average price per share, total number of shares purchased, and the approximate dollar value of shares that may yet be purchased under the plans or programs. It also mentions that the company did not purchase any shares during the specified period under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck's common stock for its treasury.
I'm sorry, but it appears that you have not sent any text yet. Can you please provide the text parts you mentioned?
I'm sorry, but it appears that I have not received any parts of the text. Please go ahead and provide the text that you would like me to summarize.
The text provides updates on changes in Other Comprehensive Income (Loss) for a company, including specific components such as Derivatives, Employee Benefit Plans, and Foreign Currency Translation Adjustment. It also includes segment reporting for the Pharmaceutical and Animal Health segments, detailing product sales figures over periods of three and nine months. Furthermore, the mention of a spin-off of Organon and financial statement notes, such as the reclassification of foreign currency cash flow hedges and amortization details, are highlighted. Updates on various pharmaceutical products and segments of Merck are provided, with information on product approvals, sales growth, and changes in sales for products like Vaxneuvance, Bridion, Zerbaxa, Adempas, Verquvo, Lagevrio, and Isentress/Isentress HD. Sales of animal health products also saw changes, and the company's costs, expenses, and factors contributing to an increase in expenses in 2022 compared to 2021 were discussed.
The text provided is the section of a document detailing various exhibit numbers related to Merck & Co., Inc., including a restated Certificate of Incorporation, By-Laws, certifications of the Chief Executive Officer and Chief Financial Officer, XBRL documents, and a cover page interactive data file. It also includes signatures of company executives on behalf of the registrant.
